Mesothelioma Clinical Trial: MESODEC
Key Takeaways MESODEC is a Phase II clinical trial that combines a dendritic cell vaccine with platinum/pemetrexed chemotherapy to treat malignant pleural mesothelioma. The trial targets the Wilms’ tumor gene (WT1) — a protein strongly associated with mesothelioma. WT1 expression can both confirm a mesothelioma diagnosis and help predict prognosis. The vaccine works by loading […]
